FibroBiologics, Inc. Common Stock (FBLG) 10-Q 12 Nov 24 2024 Q3 Quarterly report Financial data

Cover

Cover - $ / shares	9 Months Ended
	Sep. 30, 2024	Nov. 11, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-41934
Entity Registrant Name	FibroBiologics, Inc.
Entity Central Index Key	0001958777
Entity Tax Identification Number	86-3329066
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	455 E. Medical Center Blvd
Entity Address, Address Line Two	Suite 300
Entity Address, City or Town	Houston
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	77598
City Area Code	(281)
Local Phone Number	651-5150
Title of 12(b) Security	Common Stock, $0.00001 par value
Trading Symbol	FBLG
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		34,659,125
Entity Listing, Par Value Per Share	$ 0.00001

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 7,827	$ 9,163
Prepaid expenses	353	36
Other current assets	18	16
Total current assets	8,198	9,215
Property and equipment, net	772	797
Operating lease right-of-use asset, net	1,499	1,809
Total assets	10,469	11,821
Current liabilities
Accounts payable and accrued expenses	1,179	1,444
Parent company payable		141
Operating lease liability, short-term	392	362
GEM commitment fee payable	1,863
Forward contract liability	241
Liability instrument		7,236
Warrant liability	2,887
Short-term note payable	115
Total current liabilities	6,677	9,183
Operating lease liability, long-term	1,055	1,385
Total liabilities	7,732	10,568
Stockholders’ equity
Preferred Stock, value
Additional paid-in capital	35,156	25,609
Accumulated deficit	(32,419)	(24,357)
Total stockholders’ equity	2,737	1,253
Total liabilities and stockholders’ equity	10,469	11,821
Series A Preferred Stock [Member]
Stockholders’ equity
Preferred Stock, value
Series B Preferred Stock [Member]
Stockholders’ equity
Preferred Stock, value
Series B-1 Preferred Stock [Member]
Stockholders’ equity
Preferred Stock, value
Series C Preferred Stock [Member]
Stockholders’ equity
Preferred Stock, value
Nonvoting Common Stock [Member]
Stockholders’ equity
Common Stock, value		1
Voting Common Stock [Member]
Stockholders’ equity
Common Stock, value

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	10,000,000	20,000,000
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	0	8,750,000
Preferred stock, shares issued	0	8,750,000
Preferred stock, shares outstanding	0	8,750,000
Series B Preferred Stock [Member]
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	0	5,000,000
Preferred stock, shares issued	0	4,171,445
Preferred stock, shares outstanding	0	4,171,445
Series B-1 Preferred Stock [Member]
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	0	5,000,000
Preferred stock, shares issued	0	89,781
Preferred stock, shares outstanding	0	89,781
Series C Preferred Stock [Member]
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	2,500	2,500
Preferred stock, shares issued	2,500	0
Preferred stock, shares outstanding	2,500	0
Nonvoting Common Stock [Member]
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	0	30,000,000
Common stock, shares issued	0	28,230,842
Common stock, shares outstanding	0	28,230,842
Voting Common Stock [Member]
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	33,917,961	0
Common stock, shares outstanding	33,917,961	0

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating expenses:
Research and development	$ 1,213	$ 571	$ 3,148	$ 1,595
General, administrative and other	2,139	1,481	6,877	4,814
Total operating expenses	3,352	2,052	10,025	6,409
Loss from operations	(3,352)	(2,052)	(10,025)	(6,409)
Other income/(expense):
Change in fair value of warrant liability	1,927		4,349
Change in fair value of forward contract liability	849		(650)
Commitment fee expense			(1,941)
Other income/(loss)	2	(141)	31	(213)
Interest income	79		188
Interest expense	(5)		(14)	(146)
Total other income/(expense)	2,852	(141)	1,963	(359)
Net loss	(500)	(2,193)	(8,062)	(6,768)
Deemed dividend				(2,573)
Net loss attributable to common stockholders	$ (500)	$ (2,193)	$ (8,062)	$ (9,341)
Net loss per share, basic	$ (0.01)	$ (0.08)	$ (0.25)	$ (0.33)
Net loss per share, diluted	$ (0.01)	$ (0.08)	$ (0.25)	$ (0.33)
Weighted-average shares outstanding, basic	33,516,656	28,230,842	32,457,473	28,230,842
Weighted-average shares outstanding, diluted	33,516,656	28,230,842	32,457,473	28,230,842

Condensed Statements of Changes

Condensed Statements of Changes in Stockholders' Equity/(Deficit) (Unaudited) - USD ($) $ in Thousands	Parent Investment [Member]	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Preferred Stock [Member] Series B-1 Preferred Stock [Member]	Preferred Stock [Member] Series C Preferred Stock [Member]	Common Stock [Member] Nonvoting Common Stock [Member]	Common Stock [Member] Voting Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2022	$ 1,461					$ 1		$ 2,414	$ (7,872)	$ (3,996)
Balance, shares at Dec. 31, 2022		8,750,000	381,658			28,230,842
Stock-based compensation expense								448		448
Net income/ (loss)									(2,415)	(2,415)
Sale of Series B Preferred Stock, net of direct costs								4,889		4,889
Sale of Series B Preferred Stock, net of direct costs, shares			911,379
Issuance of Series B Preferred Stock for conversion of Notes and accrued interest								4,286		4,286
Issuance of Series B Preferred Stock for conversion of Notes and accrued interest, shares			799,603
Deemed dividend related to ROFN Agreement derivative liability	(1,461)							(1,112)		(2,573)
Balance at Mar. 31, 2023						$ 1		10,925	(10,287)	639
Balance, shares at Mar. 31, 2023		8,750,000	2,092,640			28,230,842
Balance at Dec. 31, 2022	1,461					$ 1		2,414	(7,872)	(3,996)
Balance, shares at Dec. 31, 2022		8,750,000	381,658			28,230,842
Net income/ (loss)										(6,768)
Balance at Sep. 30, 2023						$ 1		25,177	(14,640)	10,538
Balance, shares at Sep. 30, 2023		8,750,000	4,171,445	74,922		28,230,842
Balance at Mar. 31, 2023						$ 1		10,925	(10,287)	639
Balance, shares at Mar. 31, 2023		8,750,000	2,092,640			28,230,842
Stock-based compensation expense								448		448
Net income/ (loss)									(2,160)	(2,160)
Sale of Series B Preferred Stock, net of direct costs								10,056		10,056
Sale of Series B Preferred Stock, net of direct costs, shares			1,659,015
Issuance of Series B Preferred Stock for conversion of Notes and accrued interest								2,117		2,117
Issuance of Series B Preferred Stock for conversion of Notes and accrued interest, shares			419,790
Sale of Series B-1 Preferred Stock, net of direct costs								253		253
Sale of Series B-1 Preferred Stock, net of direct costs, shares				13,888
Balance at Jun. 30, 2023						$ 1		23,799	(12,447)	11,353
Balance, shares at Jun. 30, 2023		8,750,000	4,171,445	13,888		28,230,842
Stock-based compensation expense								437		437
Net income/ (loss)									(2,193)	(2,193)
Sale of Series B-1 Preferred Stock, net of direct costs								941		941
Sale of Series B-1 Preferred Stock, net of direct costs, shares				61,034
Balance at Sep. 30, 2023						$ 1		25,177	(14,640)	10,538
Balance, shares at Sep. 30, 2023		8,750,000	4,171,445	74,922		28,230,842
Balance at Dec. 31, 2023						$ 1		25,609	(24,357)	1,253
Balance, shares at Dec. 31, 2023		8,750,000	4,171,445	89,781		28,230,842
Issuance of Series C Preferred Stock								45		45
Issuance of Series C Preferred Stock, shares					2,500
Conversion to Voting Common Stock						$ (1)		1
Conversion to Voting Common Stock, shares			(4,171,445)	(89,781)		(28,230,842)	32,492,068
Cancellation of Series A Preferred Stock upon Direct Listing
Cancellation of Series A Preferred Stock upon Direct Listing, shares		(8,750,000)
Sale of Common Stock								2,819		2,819
Sale of Common Stock, shares							227,057
Stock-based compensation expense								480		480
Net income/ (loss)									(8,460)	(8,460)
Balance at Mar. 31, 2024								28,954	(32,817)	(3,863)
Balance, shares at Mar. 31, 2024					2,500		32,719,125
Balance at Dec. 31, 2023						$ 1		25,609	(24,357)	1,253
Balance, shares at Dec. 31, 2023		8,750,000	4,171,445	89,781		28,230,842
Net income/ (loss)										(8,062)
Balance at Sep. 30, 2024								35,156	(32,419)	2,737
Balance, shares at Sep. 30, 2024					2,500		33,917,961
Balance at Mar. 31, 2024								28,954	(32,817)	(3,863)
Balance, shares at Mar. 31, 2024					2,500		32,719,125
Stock-based compensation expense								578		578
Net income/ (loss)									898	898
Balance at Jun. 30, 2024								29,532	(31,919)	(2,387)
Balance, shares at Jun. 30, 2024					2,500		32,719,125
Sale of Common Stock								5,052		5,052
Sale of Common Stock, shares							1,198,836
Stock-based compensation expense								572		572
Net income/ (loss)									(500)	(500)
Balance at Sep. 30, 2024								$ 35,156	$ (32,419)	$ 2,737
Balance, shares at Sep. 30, 2024					2,500		33,917,961

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities
Net loss	$ (8,062)	$ (6,768)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of liability instrument and warrant liability	(4,349)
Change in fair value of forward contract liability	650
Stock-based compensation expense	1,675	1,333
Other loss on derivative liability		72
Amortization of convertible notes debt discount		81
Amortization of operating lease right-of-use asset	310	291
Depreciation expense	110	16
Changes in operating assets and liabilities:
Change in prepaid expenses	(317)	2
Change in other current assets	(2)	(91)
Change in accounts payable and accrued expenses	(265)	396
Change in commitment fee payable	1,863
Change in payable to Parent	(141)	141
Change in operating lease liability	(300)	(273)
Net cash used in operating activities	(8,828)	(4,800)
Cash flows from investing activities
Purchases of property and equipment	(85)	(493)
Net cash used in investing activities	(85)	(493)
Cash flows from financing activities
ROFN Agreement payments to Parent		(2,645)
Repayment and proceeds of note receivable from Parent		300
Proceeds from short-term borrowing	574
Repayments of short-term borrowing	(459)
Proceeds from issuance of Series B Preferred Stock, net of direct costs		14,945
Proceeds from issuance of Series B-1 Preferred Stock, net of direct costs		1,193
Proceeds from issuance of common stock, net of direct costs	7,462
Net cash provided by financing activities	7,577	13,793
Net increase/(decrease) in cash and cash equivalents	(1,336)	8,500
Cash and cash equivalents, beginning of period	9,163	2,266
Cash and cash equivalents, end of period	7,827	10,766
Supplemental disclosure of cash flow information:
Cash paid for income taxes
Cash paid for interest	14	1
Supplemental disclosure of non-cash investing and financing activities:
Issuance of Series B Preferred Stock for conversion of Notes and accrued interest		5,866
Reclassification of derivative liability for conversion of Notes to Series B Preferred Stock		538
Settlement of forward contract liability for sale of shares to GEM pursuant to Draw Down and Closing Notices	$ 409

Organization, Description of Bu

Organization, Description of Business, and Liquidity	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Organization, Description of Business, and Liquidity	1. Organization, Description of Business, and Liquidity Organization and Business FibroBiologics, Inc. (the “Company” or “FibroBiologics”) was originally formed as a limited liability company (“LLC”) under the laws of the State of Texas on April 8, 2021 (“Inception”) and then converted to a Delaware corporation on December 14, 2021. FibroBiologics is a clinical stage biotechnology company headquartered in Houston, Texas, developing innovative treatments for chronic diseases using fibroblast cells. The Company’s primary focus is the initiation and progression of preclinical studies and clinical-stage U.S. Food and Drug Administration trials related to fibroblast treatments for Wound Healing, Multiple Sclerosis, Degenerative Disc Disease, Psoriasis, Cancer, and other diseases. Prior to Inception, preclinical research and development related to these disease pathways took place under the parent company, SpinalCyte, LLC (the “Parent” or “FibroGenesis”). Direct Listing On January 31, 2024, the Company completed a direct listing of its common stock on Nasdaq (the “Direct Listing”). Upon completion of the Direct Listing, all outstanding shares of the Company’s Non-voting Common Stock, Series B Preferred Stock, and Series B-1 Preferred Stock automatically converted into shares of Voting Common Stock on a one-for-one basis, and all outstanding shares of the Company’s Series A Preferred Stock were canceled for no consideration. Going Concern and Management’s Plan The Company has incurred operating losses since Inception and expects such losses to continue in the future as it builds infrastructure, develops intellectual property, and conducts research and development activities. The Company has primarily relied on a combination of angel investors and private equity and debt placements to fund its operations. As of September 30, 2024, the Company had an accumulated deficit of $ 32,419 7,827 2,819 4,643 Segments Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. The chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. The Company operates and manages its business as a single operating segment and therefore has one

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying Unaudited Condensed Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The accompanying Unaudited Condensed Balance Sheet as of September 30, 2024, Unaudited Condensed Statements of Operations for the three and nine months ended September 30, 2024 and 2023, Unaudited Condensed Statements of Stockholders’ Equity/(Deficit) for the three and nine months ended September 30, 2024 and 2023, and Unaudited Condensed Statements of Cash Flows for the nine months ended September 30, 2024 and 2023, are unaudited. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC on February 29, 2024, which contains the audited financial statements and notes thereto. The Unaudited Condensed Financial Statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of September 30, 2024, the results of operations for the three and nine months ended September 30, 2024 and 2023, the unaudited condensed statements of stockholders’ equity/(deficit) for the three and nine months ended September 30, 2024 and 2023 and the unaudited condensed statements of cash flows for the nine months ended September 30, 2024 and 2023. The December 31, 2023, Unaudited Condensed Balance Sheet included herein was derived from the audited financial statements, but it does not include all disclosures or notes required by GAAP for complete financial statements. The financial data and other information disclosed in these notes to the unaudited condensed financial statements related to the three and nine months ended September 30, 2024 and 2023, are unaudited. Interim results are not necessarily indicative of results for an entire year or for any future period. During the period from January 1, 2021, to its formation on April 8, 2021, the Company operated as a line of business of FibroGenesis rather than as a separate stand-alone entity. Consequently, prior to the Company’s formation on April 8, 2021, the financial statements were derived from the historical accounting records of the Parent. All general and administrative expenses and research and development expenses directly associated with the business activity of the Company that were originally incurred by the Parent from January 1, 2021, through the Company’s formation on April 8, 2021, were allocated and included in the Company’s financial statements. The resulting net Parent investment was presented within stockholders’ equity/(deficit) and represented the Parent’s interest in the recorded net assets of the Company and has been eliminated through the ROFN Agreement as further described in Notes 6 and 10. In October 2023, the Company amended and restated its certificate of incorporation with the State of Delaware to immediately effect a 1-for-4 shares Use of Estimates The preparation of the Unaudited Condensed Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Unaudited Condensed Financial Statements and the reported amounts of expenses during the reporting periods. These estimates are based on information available as of the date of the Unaudited Condensed Financial Statements; therefore, actual results could differ from those estimates and assumptions. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company has significant cash balances at financial institutions, which, throughout the year, regularly exceed the federally insured limit of $ 250,000 Risks and Uncertainties The Company is subject to certain risks and uncertainties, including, but not limited to, changes in any of the following areas that the Company believes could have a material adverse effect on the future financial position or results of operations: the timing of, and the Company’s ability to advance its current and future product candidates into and through clinical development; costs and timelines associated with the manufacture of clinical supplies of the Company’s product candidates; regulatory approval and market acceptance of its product candidates; performance of third-party contract research organizations (“CROs”) and contract development and manufacturing organizations (“CDMOs”); competition from pharmaceutical companies with greater financial resources or expertise; protection of the intellectual property, litigation or claims against the Company based on intellectual property, or other factors; the need to obtain additional funding; and its ability to attract and retain employees necessary to support its growth. Disruption from the operations of CROs, CDMOs or suppliers would likely have a negative impact on the Company’s business, financial position and results of operations. Cash and Cash Equivalents Cash and cash equivalents consist of unrestricted cash balances and short-term, liquid investments with an original maturity date of three months or less at the time of purchase. The Company had $ 6,488 no Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets, generally three five years five years Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company will recognize an impairment loss only if the carrying amount is not recoverable through its undiscounted cash flows and measure any impairment loss based on the difference between the carrying amount and estimated fair value. The Company incurred no such losses for the three and nine months ended September 30, 2024 and 2023. Leases The Company determines if an arrangement is a lease at inception. An arrangement is or contains a lease if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration. If a lease is identified, classification is determined at lease commencement. Operating lease liabilities are recognized at the present value of the future lease payments at the lease commencement date. The Company’s leases do not provide an implicit interest rate and therefore the Company estimates its incremental borrowing rate to discount lease payments. The incremental borrowing rate reflects the interest rate that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments in a similar economic environment over a similar term. Operating lease right-of-use (“ROU”) assets are based on the corresponding lease liability adjusted for any lease payments made at or before commencement, initial direct costs, and lease incentives. Renewals or early terminations are not accounted for unless the Company is reasonably certain to exercise these options. Operating lease expense is recognized and the ROU asset is amortized on a straight-line basis over the lease term. Operating leases are included in operating lease right-of-use asset, operating lease liability, short-term, and operating lease liability, long-term on the Company’s Unaudited Condensed Balance Sheets. The Company has elected in accordance with Accounting Standards Codification (“ASC”) 842-20-25-2 an accounting policy to not record short-term leases, defined as those with terms of 12 months or less, on the Unaudited Condensed Balance Sheets. Rent expense recorded under leases, for financial statement purposes, is recognized on a straight-line basis over the lease term based on the most recent contractual terms available. Fair Value Measurements ASC 820, Fair Value Measurement Level 1 - Quoted market prices in active markets for identical assets or liabilities. Level 2 - Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. Level 3 - Unobservable inputs for the asset or liability (i.e., supported by little or no market activity). Level 3 inputs include management’s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk). Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Derivatives Derivative financial instruments, including the liability instrument, are recorded at fair value on the Unaudited Condensed Balance Sheets. Liability classified derivatives are remeasured at their fair value at each reporting date, with decreases or increases in the fair value recognized as other gain or loss, respectively, within the Unaudited Condensed Statements of Operations. Equity classified derivatives are not remeasured at each reporting date. If a liability classified derivative becomes eligible for reclassification to an equity classified derivative, any gains or losses recognized up to the point of reclassification are not reversed. Research and Development Research and development costs are charged to expense as incurred. Research and development costs consist of costs incurred in performing research and development activities, including salaries and bonuses, scientist recruiting costs, employee benefits, facilities costs, laboratory supplies, manufacturing expenses, preclinical expenses, research materials, and consulting and other contracted services. Costs for certain research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the Unaudited Condensed Financial Statements as prepaid or accrued research and development. Patent Costs As the Company continues to incur costs to obtain market approval of patented technology, patent costs are expensed as incurred in general, administrative and other expense in the Unaudited Condensed Statements of Operations. Costs include fees to renew or extend the term of recognized intangible assets, patent defense costs, and patent application costs. Management will continue to expense such costs until market approval is obtained through regulatory approval by the appropriate governing body. Income Taxes The Company is a C corporation, and accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to an amount that is more likely than not to be realized. Under the provisions of ASC 740-10, Income Taxes Stock-Based Compensation The Company recognizes compensation costs related to stock options granted to employees and nonemployees based on the estimated fair value of the awards on the date of grant and recognizes expense on a straight-line basis over the requisite service period, which is generally the vesting period of the award. Forfeitures are recognized as they occur. The fair value of stock options is estimated on the date of grant using a Black-Scholes option pricing model which requires management to apply judgment and make estimates, including: ● Fair Value of Common Stock ● Expected Term ● Expected Volatility ● Risk-Free Interest Rate ● Expected Dividend Emerging Growth Company With the completion of the Direct Listing, the Company is an emerging growth company (“EGC”), as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Under the JOBS Act, an EGC can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies; however, the Company may adopt new or revised accounting standards early if the standard allows for early adoption. In addition, the Company will utilize other exemptions and reduced reporting requirements provided to EGCs by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, an EGC is not required to, among other things, (i) provide an auditor’s attestation report on the Company’s system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002, (ii) provide all of the compensation disclosure that may be required of non-EGC public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis), or (iv) disclose certain executive compensation-related items, such as the correlation between executive compensation and performance and comparisons of the chief executive officer’s compensation to median employee compensation. Recently Issued Accounting Pronouncements In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures

Net Income_(Loss) Per Share Att

Net Income/(Loss) Per Share Attributable to Common Stockholders	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Net Income/(Loss) Per Share Attributable to Common Stockholders	3. Net Income/(Loss) Per Share Attributable to Common Stockholders The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company: Schedule of Basic and Diluted Net Income Loss Per Share Attributable to Common Stockholders (in thousands, except share and per share amounts) 2024 2023 2024 2023 Three Months Ended September 30, Nine Months Ended September 30, (in thousands, except share and per share amounts) 2024 2023 2024 2023 Numerator: Net loss $ (500 ) $ (2,193 ) $ (8,062 ) $ (6,768 ) Adjustment to numerator for earnings per share: Deemed dividend — — — (2,573 ) Net loss attributable to common stockholders $ (500 ) $ (2,193 ) $ (8,062 ) $ (9,341 ) Denominator: Weighted-average number of common shares outstanding, basic and diluted 33,516,656 28,230,842 32,457,473 28,230,842 Net loss per common share attributable to common stockholders, basic and diluted $ (0.01 ) $ (0.08 ) $ (0.25 ) $ (0.33 ) As further described in Note 6, the Company issued 28,230,842 227,057 1,198,836 As further described in Note 7, the Company issued 741,164 As further described in Note 10, the Company agreed to pay to FibroGenesis 15% 35 1,461 1,112 The Company had $ 5,600 10,000 0 5,600 No

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
Property and Equipment	4. Property and Equipment Property and equipment, net consist of the following: Schedule of Property and Equipment September 30, December 31, (in thousands) 2024 2023 Laboratory equipment $ 882 $ 816 Computer equipment, software, and other 47 28 Total property and equipment at cost 929 844 Less: Accumulated depreciation (157 ) (47 ) Property and equipment, net $ 772 $ 797 The useful life of laboratory equipment is five years three years 38 13 110 16

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	5. Fair Value of Financial Instruments As of December 31, 2022, the Company measured its derivative liability related to the conversion option feature in the 2022 Notes at fair value. As of September 30, 2023, $ 5,600 538 As of December 31, 2023, the Company measured its liability instrument to investors under the Share Purchase Agreement, as further described in Note 7, at $ 7,236 20,963 2,887 The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy: Schedule of Financial Liabilities Measured at Fair Value (in thousands) Level 1 Level 2 Level 3 Total Fair Value Measurement as of September 30, 2024 (in thousands) Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 6,488 $ — $ — $ 6,488 Total assets fair value $ 6,488 $ — $ — $ 6,488 Liabilities: Forward contract liability $ — $ — $ 241 $ 241 Warrant liability — — 2,887 2,887 Total liabilities fair value $ — $ — $ 3,128 $ 3,128 (in thousands) Level 1 Level 2 Level 3 Total Fair Value Measurement as of December 31, 2023 (in thousands) Level 1 Level 2 Level 3 Total Liabilities: Liability instrument $ — $ — $ 7,236 $ 7,236 Total fair value $ — $ — $ 7,236 $ 7,236 Total liabilities fair value $ — $ — $ 7,236 $ 7,236 The following table summarizes the activity related to Level 3 financial liabilities for the nine months ended September 30, 2024: Schedule of Transfers In and Out of Level 3 Financial Liabilities (in thousands) Liability Instrument Forward Contract Liability Warrant Liability Fair value at December 31, 2023 $ 7,236 $ — $ — Fair value, balance $ 7,236 — $ — Bifurcation of the liability instrument upon Direct Listing (7,236 ) 7,236 Increase in Warrant liability at issuance January 31, 2024 — — 13,727 Forward contract liability as of June 30, 2024 — 1,500 — Change in fair value of Forward contract liability — (1,259 ) — Change in fair value of Warrant liability — — (18,076 ) Fair value at September 30, 2024 $ — $ 241 $ 2,887 Fair value, balance $ — 241 $ 2,887 As of December 31, 2023, the liability instrument included the contingent warrant liability and the contingent put option (forward contract) liability as a single unit of account. The liability instrument value was determined using a Black-Scholes valuation model and management’s assumption of a 50% likelihood as of December 31, 2023, of becoming a public company prior to the expiration of the Stock Purchase Agreement. Inputs used in the Black-Scholes valuation model included an estimated number of warrants, an assumed common stock share price of $ 15.00 five 0 3.84 five 96 Upon completion of the Direct Listing on January 31, 2024, the warrant liability and the forward contract liability were no longer contingent and were bifurcated out of the liability instrument and treated as separate units of account. As of January 31, 2024, the warrant liability value for the warrant issued to GEM Yield Bahamas Limited (“GYBL”) was determined using a Black-Scholes valuation model. Inputs used in the Black-Scholes valuation model included the 1,299,783 21.54 five 0 3.91 five 97 1,299,783 3.09 four 0 3.58 100 As further described in Note 7, the Company issued a Draw Down Notice on September 12, 2024, for 1,000,000 258,836 741,164 3.25 3.25 10 The carrying amounts of cash and cash equivalents, prepaid expenses, other current assets, accounts payable, accrued expenses, and Parent company payable and receivable approximate their fair values due to their short-term maturities. There were no transfers in or out of Level 1, Level 2 or Level 3 assets and liabilities for the nine months ended September 30, 2024 and for the year ended December 31, 2023.

Stockholders_ Equity_(Deficit)

Stockholders’ Equity/(Deficit) / Net Parent Investment	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Stockholders’ Equity/(Deficit) / Net Parent Investment	6. Stockholders’ Equity/(Deficit) / Net Parent Investment Authorized Capital – 10,000,000 20,000,000 8,750,000 35,000 62,500,000 28,230,842 28,179,592 51,250 168 In December 2022, the Company amended its Certificate of Incorporation to authorize 2,500,000 In January 2023, to reflect the ROFN Agreement with its Parent, as further discussed in Note 10, the Company amended its Certificate of Incorporation to a) make the Series “B” Preferred Stock liquidation preference equal to Series “A” Preferred Stock, and b) to provide that upon IPO, Direct Listing, or Sale of the Company, the Series “A” Preferred Stock would be canceled for no consideration. In March 2023, the Company accepted a stock subscription to purchase shares of Series B Preferred Stock for $ 10,000 10,000 In April 2023, the Company amended its Certificate of Incorporation to authorize 10,000,000 5,000,000 5,000,000 In October 2023, the Company amended and restated its certificate of incorporation with the State of Delaware to increase to 100,000,000 0.00001 30,000,000 0.00001 2,500 0.00001 The Series C Preferred Stock had no voting rights prior to an IPO, and 13,000 votes per share upon closing of an IPO The Series C Preferred Stock is not entitled to dividends, has a liquidation preference of $ 18.00 In January 2024, the Company issued 2,500 On January 31, 2024, the Company completed its Direct Listing, which qualified as an IPO transaction. As a result of the IPO, the outstanding Series A Preferred Stock shares were canceled for no consideration and the outstanding Series B Preferred Stock, Series B-1 Preferred Stock, and non-voting common stock shares were all converted 1:1 into shares of voting common stock. In addition, the Series C Preferred Stock voting rights increased from none to 13,000 votes per share shares will automatically convert 1:1 into common stock In August 2024, the Company amended and restated its certificate of incorporation with the State of Delaware to eliminate its non-voting common stock, Series A Preferred Stock, Series B Preferred Stock, and Series B-1 Preferred Stock, and to reduce to 10,000,000 0.00001 2,500

Share Subscription Agreement

Share Subscription Agreement	9 Months Ended
	Sep. 30, 2024
Share Subscription Agreement
Share Subscription Agreement	7. Share Subscription Agreement On November 12, 2021, the Company entered into a Share Purchase Agreement with certain investors for the sale of up to $ 100,000 2 700,000 The Company may request a drawdown, or sale of common stock shares to the investors, over the five-year term of this agreement following the public listing unless terminated earlier. The amount of the drawdowns requested is limited by the trading volumes of the Company’s common stock over the 30-day period preceding the drawdown, and the price per share is equal to 90% of the average price per share over that same period. A 1% fee was due to the investors if the Company were sold in a private sale transaction rather than completing a public listing of its shares. After completion of its public listing on January 31, 2024, and during the three months ended March 31, 2024, the Company sold a total of 227,057 2,819 Upon completion of its public listing the Company recorded a payable of $ 2,000 1,941 On June 27, 2024, the Company issued 3,000,000 shares of Common Stock to facilitate a Draw Down Notice under the Share Purchase Agreement. The Company recorded upon issuance a $ 1,410 thousand fair value of the forward contract liability for its requirement to sell up to 3,000,000 shares to the investor at 90 % of the average closing price per share during the Draw Down Period based upon the number of shares, the closing price per share of $ 4.66 on June 27, 2024, and the 10 % discount to be provided to the investor purchasing the shares from the Company. The fair value of the forward contract liability was remeasured to $ 638 840,000 shares accepted, the $. 4.85 4.09 after the 10 % discount provided to the investor, and the forward contract liability was eliminated. GEM returned 560,000 shares to the Company, which canceled those shares, and the remaining 1,600,000 shares were retained by GEM to facilitate a subsequent Draw Down Notice. On July 12, 2024, the Company issued a Draw Down Notice for 1,600,000 shares. The Company recorded upon issuance a $ 758 thousand fair value of the forward contract liability for its requirement to sell up to 1,600,000 shares to the investor at 90 % of the average closing price per share during the Draw Down Period based upon the number of shares, the closing price per share of $ 4.74 on July 12, 2024, and the 10 % discount to be provided to the investor purchasing the shares from the Company. The fair value of the forward contract liability was remeasured to a $ 286 thousand asset at August 26, 2024, upon receipt of the Closing Notice from GEM, based upon the 100,000 shares accepted, the $ 1.65 4.51 after the 10 % discount provided to the investor, and the forward contract liability was eliminated. GEM returned 500,000 shares to the Company, which canceled those shares, and the remaining 1,000,000 shares were retained by GEM to facilitate a subsequent Draw Down Notice. On September 12, 2024, the Company issued a Draw Down Notice for 1,000,000 shares. The Company recorded upon issuance a $ 325 thousand fair value of the forward contract liability for its requirement to sell up to 1,000,000 shares to the investor at 90 % of the average closing price per share during the Draw Down Period based upon the number of shares, a price per share of $ 3.25 , based on the floor price of $ 3.25 per share because the closing price was lower than the floor price on September 12, 2024, and the 10 % discount to be provided to the investor purchasing the shares from the Company. Upon receipt of an initial Closing Notice from GEM on September 26, 2024, the fair value of the portion of the forward contract liability covered by the Closing Notice was remeasured to $ 57 thousand at, based upon the 258,836 shares accepted, the $ 3.14 2.93 after the 10 % discount provided to the investor, and that portion of the forward contract liability was eliminated. The September 12, 2024, Draw Down Notice remained open for 741,164 shares, which will either be sold to GEM pursuant to a future Closing Notice or returned to the Company. The fair value of the of the remaining portion of the forward contract liability was remeasured at September 30, 2024, based on the remaining 741,164 3.25 3.25 10

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	8. Income Taxes The Company did not record any tax provision or benefit for the three and nine months ended September 30, 2024 or 2023. Management has evaluated the positive and negative evidence bearing upon the realizability of the Company’s net deferred tax assets and has determined that it is more likely than not that the Company will not recognize the benefits of the net deferred tax assets. As a result, the Company has recorded a full valuation allowance at September 30, 2024, and December 31, 2023.

Leases, Commitments and Conting

Leases, Commitments and Contingencies	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Leases, Commitments and Contingencies	9. Leases, Commitments and Contingencies In October 2022, the Company entered into a lease agreement for office space with a term of 62 2,293 7.5% In June 2023, the Company entered into a new lease for temporary lab and office space for its research operations. This lease has a term of 12 6 7 8 12 7 Rent expense for the nine months ended September 30, 2024 and 2023, was $ 466 504 1,629 74 As of September 30, 2024, future minimum payments during the remaining period and the next five years are as follows (in thousands): Schedule of Operating Lease Liabilities Future minimum payments 2024 $ 88 2025 488 2026 544 2027 509 2028 — Thereafter — Total lease payments 1,629 Less: Imputed interest (182 ) Total lease liabilities 1,447 Less: Current lease liabilities (392 ) Total non-current lease liabilities $ 1,055

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2024
Related Party Transactions [Abstract]
Related Party Transactions	10. Related Party Transactions As described in Note 6, the Company acquired from FibroGenesis certain in-process research and development and patent assets through Patent Assignment and Intellectual Property Cross-License Agreements. The Patent Assignment Agreement transferred the right, title and interest in and to certain patents from FibroGenesis to the Company for further development. The Intellectual Property Cross-License Agreement grants to the Company exclusive rights to patents owned by FibroGenesis in a limited field of use, which includes the diagnosis, treatment, prevention and palliation of a) spinal diseases, disorders, or conditions, b) cancer, c) orthopedics diseases, disorders or conditions, and d) multiple sclerosis. In January 2023, the Company entered into an Agreement Regarding Right of First Negotiation (“ROFN Agreement”) with its Parent, FibroGenesis. In exchange for FibroGenesis’ consent to amend the Certificate of Incorporation to a) eliminate upon IPO, Direct Listing, or Sale of the Company the Series A Preferred Stock $ 35,000 15% 2,573 2,645 15% 15 141 no 0 141

Share-Based Compensation

Share-Based Compensation	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	11. Share-Based Compensation The Company adopted on August 10, 2022, and the stockholders approved on August 18, 2022, the 2022 Stock Plan (the “Plan”). The Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other stock awards. The Plan, through the grant of stock awards, is intended to help the Company secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Company and provide a means by which the eligible recipients may benefit from increases in value of the common stock. In September 2022, the Company issued a total of 101,250 3.28 3,689,750 2.28 2,500 3.28 216,875 13.00 6,875 6.73 25,000 1.73 As of September 30, 2024, and December 31, 2023, there were 8,467,889 8,711,500 Stock-based compensation expense is recognized in the Unaudited Condensed Statements of Operations as follows: Schedule of Stock Based Compensation Expense Three Months Ended September 30, Nine Months Ended September 30, (in thousands of dollars) 2024 2023 2024 2023 Research and development $ 82 $ 66 $ 248 $ 196 General, administrative and other 490 374 1,383 1,137 Total stock-based compensation expense $ 572 $ 440 $ 1,631 $ 1,333 In addition to the $ 1,631 45 2,500 Unrecognized stock-based compensation costs related to unvested awards and the weighted-average period over which the costs are expected to be recognized as of September 30, 2024, are as follows: Schedule of Unvested Awards and Weighted Average Period Stock Options Unrecognized stock-based compensation expense (in thousands) $ 5,766 Expected weighted-average period compensation costs to be recognized (years) 2.6 A summary of the Company’s stock option activity is as follows: Schedule of Stock Option Activity Stock Options Weighted-Average Exercise Price per Share Weighted-Average Remaining Contractual Life (years) Aggregate Intrinsic Value (in thousands) Outstanding as of December 31, 2023 3,788,500 $ 2.31 8.4 $ 2,989 Granted 248,750 $ 11.69 9.5 $ 34 Exercised — $ — — $ — Forfeited/Cancelled (5,139 ) $ 12.74 9.4 $ — Outstanding as of September 30, 2024 4,032,111 $ 2.88 8.4 $ 3,023 Exercisable as of September 30, 2024 1,696,210 $ 2.33 8.4 $ 1,307 The fair value of stock options granted to employees, directors, and consultants was estimated on the date of grant using the Black-Scholes option pricing model using the following assumptions: Schedule of Fair Value of Option Granted Black Scholes Assumptions: Nine Months Ended September 30, 2024 Nine Months Ended September 30, 2023 Risk-free interest rate 3.7 4.3 % 3.9 % Expected volatility 97 101 % 90 % Expected term (years) 5.5 7.0 7.0 Expected dividend 0 % 0 % During the nine months ended September 30, 2024, the weighted-average grant date fair value of the options granted was $ 9.70

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events The Company has evaluated subsequent events through November 12 unaudited condensed statements u c , other than the following On October 18, 2024, the Company received a Closing Notice from GEM to purchase 15,683 2.91 46

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying Unaudited Condensed Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The accompanying Unaudited Condensed Balance Sheet as of September 30, 2024, Unaudited Condensed Statements of Operations for the three and nine months ended September 30, 2024 and 2023, Unaudited Condensed Statements of Stockholders’ Equity/(Deficit) for the three and nine months ended September 30, 2024 and 2023, and Unaudited Condensed Statements of Cash Flows for the nine months ended September 30, 2024 and 2023, are unaudited. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC on February 29, 2024, which contains the audited financial statements and notes thereto. The Unaudited Condensed Financial Statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of September 30, 2024, the results of operations for the three and nine months ended September 30, 2024 and 2023, the unaudited condensed statements of stockholders’ equity/(deficit) for the three and nine months ended September 30, 2024 and 2023 and the unaudited condensed statements of cash flows for the nine months ended September 30, 2024 and 2023. The December 31, 2023, Unaudited Condensed Balance Sheet included herein was derived from the audited financial statements, but it does not include all disclosures or notes required by GAAP for complete financial statements. The financial data and other information disclosed in these notes to the unaudited condensed financial statements related to the three and nine months ended September 30, 2024 and 2023, are unaudited. Interim results are not necessarily indicative of results for an entire year or for any future period. During the period from January 1, 2021, to its formation on April 8, 2021, the Company operated as a line of business of FibroGenesis rather than as a separate stand-alone entity. Consequently, prior to the Company’s formation on April 8, 2021, the financial statements were derived from the historical accounting records of the Parent. All general and administrative expenses and research and development expenses directly associated with the business activity of the Company that were originally incurred by the Parent from January 1, 2021, through the Company’s formation on April 8, 2021, were allocated and included in the Company’s financial statements. The resulting net Parent investment was presented within stockholders’ equity/(deficit) and represented the Parent’s interest in the recorded net assets of the Company and has been eliminated through the ROFN Agreement as further described in Notes 6 and 10. In October 2023, the Company amended and restated its certificate of incorporation with the State of Delaware to immediately effect a 1-for-4 shares
Use of Estimates	Use of Estimates The preparation of the Unaudited Condensed Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Unaudited Condensed Financial Statements and the reported amounts of expenses during the reporting periods. These estimates are based on information available as of the date of the Unaudited Condensed Financial Statements; therefore, actual results could differ from those estimates and assumptions.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company has significant cash balances at financial institutions, which, throughout the year, regularly exceed the federally insured limit of $ 250,000
Risks and Uncertainties	Risks and Uncertainties The Company is subject to certain risks and uncertainties, including, but not limited to, changes in any of the following areas that the Company believes could have a material adverse effect on the future financial position or results of operations: the timing of, and the Company’s ability to advance its current and future product candidates into and through clinical development; costs and timelines associated with the manufacture of clinical supplies of the Company’s product candidates; regulatory approval and market acceptance of its product candidates; performance of third-party contract research organizations (“CROs”) and contract development and manufacturing organizations (“CDMOs”); competition from pharmaceutical companies with greater financial resources or expertise; protection of the intellectual property, litigation or claims against the Company based on intellectual property, or other factors; the need to obtain additional funding; and its ability to attract and retain employees necessary to support its growth. Disruption from the operations of CROs, CDMOs or suppliers would likely have a negative impact on the Company’s business, financial position and results of operations.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of unrestricted cash balances and short-term, liquid investments with an original maturity date of three months or less at the time of purchase. The Company had $ 6,488 no
Property and Equipment	Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets, generally three five years five years Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company will recognize an impairment loss only if the carrying amount is not recoverable through its undiscounted cash flows and measure any impairment loss based on the difference between the carrying amount and estimated fair value. The Company incurred no such losses for the three and nine months ended September 30, 2024 and 2023.
Leases	Leases The Company determines if an arrangement is a lease at inception. An arrangement is or contains a lease if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration. If a lease is identified, classification is determined at lease commencement. Operating lease liabilities are recognized at the present value of the future lease payments at the lease commencement date. The Company’s leases do not provide an implicit interest rate and therefore the Company estimates its incremental borrowing rate to discount lease payments. The incremental borrowing rate reflects the interest rate that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments in a similar economic environment over a similar term. Operating lease right-of-use (“ROU”) assets are based on the corresponding lease liability adjusted for any lease payments made at or before commencement, initial direct costs, and lease incentives. Renewals or early terminations are not accounted for unless the Company is reasonably certain to exercise these options. Operating lease expense is recognized and the ROU asset is amortized on a straight-line basis over the lease term. Operating leases are included in operating lease right-of-use asset, operating lease liability, short-term, and operating lease liability, long-term on the Company’s Unaudited Condensed Balance Sheets. The Company has elected in accordance with Accounting Standards Codification (“ASC”) 842-20-25-2 an accounting policy to not record short-term leases, defined as those with terms of 12 months or less, on the Unaudited Condensed Balance Sheets. Rent expense recorded under leases, for financial statement purposes, is recognized on a straight-line basis over the lease term based on the most recent contractual terms available.
Fair Value Measurements	Fair Value Measurements ASC 820, Fair Value Measurement Level 1 - Quoted market prices in active markets for identical assets or liabilities. Level 2 - Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. Level 3 - Unobservable inputs for the asset or liability (i.e., supported by little or no market activity). Level 3 inputs include management’s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk). Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
Derivatives	Derivatives Derivative financial instruments, including the liability instrument, are recorded at fair value on the Unaudited Condensed Balance Sheets. Liability classified derivatives are remeasured at their fair value at each reporting date, with decreases or increases in the fair value recognized as other gain or loss, respectively, within the Unaudited Condensed Statements of Operations. Equity classified derivatives are not remeasured at each reporting date. If a liability classified derivative becomes eligible for reclassification to an equity classified derivative, any gains or losses recognized up to the point of reclassification are not reversed.
Research and Development	Research and Development Research and development costs are charged to expense as incurred. Research and development costs consist of costs incurred in performing research and development activities, including salaries and bonuses, scientist recruiting costs, employee benefits, facilities costs, laboratory supplies, manufacturing expenses, preclinical expenses, research materials, and consulting and other contracted services. Costs for certain research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the Unaudited Condensed Financial Statements as prepaid or accrued research and development.
Patent Costs	Patent Costs As the Company continues to incur costs to obtain market approval of patented technology, patent costs are expensed as incurred in general, administrative and other expense in the Unaudited Condensed Statements of Operations. Costs include fees to renew or extend the term of recognized intangible assets, patent defense costs, and patent application costs. Management will continue to expense such costs until market approval is obtained through regulatory approval by the appropriate governing body.
Income Taxes	Income Taxes The Company is a C corporation, and accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to an amount that is more likely than not to be realized. Under the provisions of ASC 740-10, Income Taxes
Stock-Based Compensation	Stock-Based Compensation The Company recognizes compensation costs related to stock options granted to employees and nonemployees based on the estimated fair value of the awards on the date of grant and recognizes expense on a straight-line basis over the requisite service period, which is generally the vesting period of the award. Forfeitures are recognized as they occur. The fair value of stock options is estimated on the date of grant using a Black-Scholes option pricing model which requires management to apply judgment and make estimates, including: ● Fair Value of Common Stock ● Expected Term ● Expected Volatility ● Risk-Free Interest Rate ● Expected Dividend
Emerging Growth Company	Emerging Growth Company With the completion of the Direct Listing, the Company is an emerging growth company (“EGC”), as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Under the JOBS Act, an EGC can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies; however, the Company may adopt new or revised accounting standards early if the standard allows for early adoption. In addition, the Company will utilize other exemptions and reduced reporting requirements provided to EGCs by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, an EGC is not required to, among other things, (i) provide an auditor’s attestation report on the Company’s system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002, (ii) provide all of the compensation disclosure that may be required of non-EGC public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis), or (iv) disclose certain executive compensation-related items, such as the correlation between executive compensation and performance and comparisons of the chief executive officer’s compensation to median employee compensation.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures

Net Income_(Loss) Per Share A_2

Net Income/(Loss) Per Share Attributable to Common Stockholders (Tables)	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Income Loss Per Share Attributable to Common Stockholders	The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company: Schedule of Basic and Diluted Net Income Loss Per Share Attributable to Common Stockholders (in thousands, except share and per share amounts) 2024 2023 2024 2023 Three Months Ended September 30, Nine Months Ended September 30, (in thousands, except share and per share amounts) 2024 2023 2024 2023 Numerator: Net loss $ (500 ) $ (2,193 ) $ (8,062 ) $ (6,768 ) Adjustment to numerator for earnings per share: Deemed dividend — — — (2,573 ) Net loss attributable to common stockholders $ (500 ) $ (2,193 ) $ (8,062 ) $ (9,341 ) Denominator: Weighted-average number of common shares outstanding, basic and diluted 33,516,656 28,230,842 32,457,473 28,230,842 Net loss per common share attributable to common stockholders, basic and diluted $ (0.01 ) $ (0.08 ) $ (0.25 ) $ (0.33 )

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, net consist of the following: Schedule of Property and Equipment September 30, December 31, (in thousands) 2024 2023 Laboratory equipment $ 882 $ 816 Computer equipment, software, and other 47 28 Total property and equipment at cost 929 844 Less: Accumulated depreciation (157 ) (47 ) Property and equipment, net $ 772 $ 797

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of Financial Liabilities Measured at Fair Value	The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy: Schedule of Financial Liabilities Measured at Fair Value (in thousands) Level 1 Level 2 Level 3 Total Fair Value Measurement as of September 30, 2024 (in thousands) Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 6,488 $ — $ — $ 6,488 Total assets fair value $ 6,488 $ — $ — $ 6,488 Liabilities: Forward contract liability $ — $ — $ 241 $ 241 Warrant liability — — 2,887 2,887 Total liabilities fair value $ — $ — $ 3,128 $ 3,128 (in thousands) Level 1 Level 2 Level 3 Total Fair Value Measurement as of December 31, 2023 (in thousands) Level 1 Level 2 Level 3 Total Liabilities: Liability instrument $ — $ — $ 7,236 $ 7,236 Total fair value $ — $ — $ 7,236 $ 7,236 Total liabilities fair value $ — $ — $ 7,236 $ 7,236
Schedule of Transfers In and Out of Level 3 Financial Liabilities	The following table summarizes the activity related to Level 3 financial liabilities for the nine months ended September 30, 2024: Schedule of Transfers In and Out of Level 3 Financial Liabilities (in thousands) Liability Instrument Forward Contract Liability Warrant Liability Fair value at December 31, 2023 $ 7,236 $ — $ — Fair value, balance $ 7,236 — $ — Bifurcation of the liability instrument upon Direct Listing (7,236 ) 7,236 Increase in Warrant liability at issuance January 31, 2024 — — 13,727 Forward contract liability as of June 30, 2024 — 1,500 — Change in fair value of Forward contract liability — (1,259 ) — Change in fair value of Warrant liability — — (18,076 ) Fair value at September 30, 2024 $ — $ 241 $ 2,887 Fair value, balance $ — 241 $ 2,887

Leases, Commitments and Conti_2

Leases, Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Schedule of Operating Lease Liabilities Future minimum payments	As of September 30, 2024, future minimum payments during the remaining period and the next five years are as follows (in thousands): Schedule of Operating Lease Liabilities Future minimum payments 2024 $ 88 2025 488 2026 544 2027 509 2028 — Thereafter — Total lease payments 1,629 Less: Imputed interest (182 ) Total lease liabilities 1,447 Less: Current lease liabilities (392 ) Total non-current lease liabilities $ 1,055

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Stock Based Compensation Expense	Stock-based compensation expense is recognized in the Unaudited Condensed Statements of Operations as follows: Schedule of Stock Based Compensation Expense Three Months Ended September 30, Nine Months Ended September 30, (in thousands of dollars) 2024 2023 2024 2023 Research and development $ 82 $ 66 $ 248 $ 196 General, administrative and other 490 374 1,383 1,137 Total stock-based compensation expense $ 572 $ 440 $ 1,631 $ 1,333
Schedule of Unvested Awards and Weighted Average Period	Unrecognized stock-based compensation costs related to unvested awards and the weighted-average period over which the costs are expected to be recognized as of September 30, 2024, are as follows: Schedule of Unvested Awards and Weighted Average Period Stock Options Unrecognized stock-based compensation expense (in thousands) $ 5,766 Expected weighted-average period compensation costs to be recognized (years) 2.6
Schedule of Stock Option Activity	A summary of the Company’s stock option activity is as follows: Schedule of Stock Option Activity Stock Options Weighted-Average Exercise Price per Share Weighted-Average Remaining Contractual Life (years) Aggregate Intrinsic Value (in thousands) Outstanding as of December 31, 2023 3,788,500 $ 2.31 8.4 $ 2,989 Granted 248,750 $ 11.69 9.5 $ 34 Exercised — $ — — $ — Forfeited/Cancelled (5,139 ) $ 12.74 9.4 $ — Outstanding as of September 30, 2024 4,032,111 $ 2.88 8.4 $ 3,023 Exercisable as of September 30, 2024 1,696,210 $ 2.33 8.4 $ 1,307
Schedule of Fair Value of Option Granted Black Scholes	The fair value of stock options granted to employees, directors, and consultants was estimated on the date of grant using the Black-Scholes option pricing model using the following assumptions: Schedule of Fair Value of Option Granted Black Scholes Assumptions: Nine Months Ended September 30, 2024 Nine Months Ended September 30, 2023 Risk-free interest rate 3.7 4.3 % 3.9 % Expected volatility 97 101 % 90 % Expected term (years) 5.5 7.0 7.0 Expected dividend 0 % 0 %

Organization, Description of _2

Organization, Description of Business, and Liquidity (Details Narrative) $ in Thousands			1 Months Ended		3 Months Ended	9 Months Ended
	Sep. 12, 2024 USD ($)	Jul. 12, 2024 USD ($)	Mar. 31, 2024 USD ($)	Feb. 29, 2024 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2024 USD ($) Segment	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Accounting Policies [Abstract]
Accumulated deficit					$ 32,419	$ 32,419		$ 24,357
Cash and cash equivalents					7,827	7,827		$ 9,163
Proceeds from issuance of common stock, net of costs	$ 325	$ 758	$ 2,819	$ 2,819		$ 7,462
Adjustments to additional paid in capital					$ 4,643
Number of reportable segments | Segment						1

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	1 Months Ended
	Oct. 31, 2023	Sep. 30, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Reverse stock split	1-for-4 shares
Federally insured limit		$ 250,000
Cash equivalents		$ 6,488,000	$ 0
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life		5 years
Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life		3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life		5 years

Schedule of Basic and Diluted N

Schedule of Basic and Diluted Net Income Loss Per Share Attributable to Common Stockholders (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Earnings Per Share [Abstract]
Net loss	$ (500)	$ 898	$ (8,460)	$ (2,193)	$ (2,160)	$ (2,415)	$ (8,062)	$ (6,768)
Deemed dividend								(2,573)
Net loss attributable to common stockholders	$ (500)			$ (2,193)			$ (8,062)	$ (9,341)
Weighted-average number of common shares outstanding, basic	33,516,656			28,230,842			32,457,473	28,230,842
Weighted-average number of common shares outstanding, diluted	33,516,656			28,230,842			32,457,473	28,230,842
Net loss per common share attributable to common stockholders, basic	$ (0.01)			$ (0.08)			$ (0.25)	$ (0.33)
Net loss per common share attributable to common stockholders, diluted	$ (0.01)			$ (0.08)			$ (0.25)	$ (0.33)

Net Income_(Loss) Per Share A_3

Net Income/(Loss) Per Share Attributable to Common Stockholders (Details Narrative) - USD ($) $ in Thousands

1 Months Ended

2 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Dec. 26, 2024

Dec. 09, 2024

Sep. 26, 2024

Sep. 12, 2024

Aug. 26, 2024

Jul. 12, 2024

Aug. 18, 2022

Jan. 31, 2023

Aug. 31, 2022

Mar. 31, 2024

Sep. 30, 2024

Sep. 30, 2023

Mar. 31, 2023

Sep. 30, 2024

Sep. 30, 2023

Dec. 31, 2022

Dec. 31, 2023

Jan. 01, 2023

Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]

Number of shares issued

258,836

1,000,000

258,836

1,000,000

100,000

1,600,000

Number of remaining shares issued

741,164

741,164

1,000,000

Preferred stock, redemption amount

$ 2,573

Convertible notes outstanding

$ 5,600

Capital stock issued in excess

$ 10,000

Parent Investment [Member]

Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]

Preferred stock, redemption amount

1,461

Additional Paid-in Capital [Member]

Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]

Preferred stock, redemption amount

$ 1,112

Fibro Genesis [Member]

Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]

Proceeds from equity investments in percentage

15%

15%

Gem Global Yield LLC SCS [Member]

Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]

Number of shares issued

227,057

1,198,836

Nonvoting Common Stock [Member]

Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]

Number of shares issued

28,230,842

28,179,592

28,230,842

Series A Preferred Stock [Member]

Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]

Preferred stock liquidation value

$ 35,000

$ 35,000

$ 35,000

Series B Preferred Stock [Member]

Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]

Convertible into preferred shares

$ 0

$ 0

$ 0

$ 5,600

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Total property and equipment at cost	$ 929	$ 844
Less: Accumulated depreciation	(157)	(47)
Property and equipment, net	772	797
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment at cost	882	816
Computer Equipment, Software, and Other [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment at cost	$ 47	$ 28

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 38	$ 13	$ 110	$ 16
Laboratary Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	5 years		5 years
Computer Equipment, Software, and Other [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	3 years		3 years

Schedule of Financial Liabiliti

Schedule of Financial Liabilities Measured at Fair Value (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023
Assets:
Cash equivalents	$ 6,488
Total assets fair value	6,488
Liabilities:
Forward contract liability	241
Warrant liability	2,887		$ 2,573
Total liabilities fair value	3,128	$ 7,236
Liability instrument		7,236
Fair Value, Inputs, Level 1 [Member]
Assets:
Cash equivalents	6,488
Total assets fair value	6,488
Liabilities:
Forward contract liability
Warrant liability
Total liabilities fair value
Liability instrument
Fair Value, Inputs, Level 2 [Member]
Assets:
Cash equivalents
Total assets fair value
Liabilities:
Forward contract liability
Warrant liability
Total liabilities fair value
Liability instrument
Fair Value, Inputs, Level 3 [Member]
Assets:
Cash equivalents
Total assets fair value
Liabilities:
Forward contract liability	241
Warrant liability	2,887
Total liabilities fair value	$ 3,128	7,236
Liability instrument		$ 7,236

Schedule of Transfers In and Ou

Schedule of Transfers In and Out of Level 3 Financial Liabilities (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)
Liability Instrument [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value, balance	$ 7,236
Liability Instrument [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value, balance	7,236
Bifurcation of the liability instrument upon Direct Listing	(7,236)
Increase in Warrant liability at issuance January 31, 2024
Forward contract liability as of June 30, 2024
Change in fair value of Forward contract liability
Change in fair value of Warrant liability
Fair value, balance
Forward Contract Liability [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value, balance
Increase in Warrant liability at issuance January 31, 2024
Forward contract liability as of June 30, 2024	1,500
Change in fair value of Forward contract liability	(1,259)
Change in fair value of Warrant liability
Fair value, balance	241
Warrant Liability [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value, balance	2,887
Warrant Liability [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value, balance
Bifurcation of the liability instrument upon Direct Listing	7,236
Increase in Warrant liability at issuance January 31, 2024	13,727
Forward contract liability as of June 30, 2024
Change in fair value of Forward contract liability
Change in fair value of Warrant liability	(18,076)
Fair value, balance	$ 2,887

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Details Narrative) $ / shares in Units, $ in Thousands							2 Months Ended	3 Months Ended	9 Months Ended
	Dec. 26, 2024 shares	Dec. 09, 2024 shares	Sep. 26, 2024 $ / shares shares	Sep. 12, 2024 $ / shares shares	Aug. 26, 2024 $ / shares shares	Jul. 12, 2024 $ / shares shares	Mar. 31, 2024 $ / shares shares	Sep. 30, 2024 USD ($) shares	Sep. 30, 2023 USD ($)	Aug. 31, 2024 $ / shares	Jun. 30, 2024 $ / shares	Jan. 31, 2024 USD ($) shares	Dec. 31, 2023 USD ($)	Aug. 31, 2023 $ / shares	Feb. 28, 2023 $ / shares	Sep. 30, 2022 $ / shares
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Number of shares issued | shares	258,836	1,000,000	258,836	1,000,000	100,000	1,600,000
Number of shares | shares			741,164	741,164	1,000,000
Share price | $ / shares			$ 3.25	$ 3.25	$ 1.65	$ 4.74	$ 13			$ 1.73	$ 6.73			$ 3.28	$ 2.28	$ 3.28
Floor price | $ / shares			$ 3.25	$ 3.25
Discount percentage			10%	10%	10%	10%
Gem Global Yield LLC SCS [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Number of shares issued | shares							227,057	1,198,836
Gem Global Yield LLC SCS [Member] | Warrant [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Number of warrants issued | shares								1,299,783				1,299,783
Measurement Input, Share Price [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Warrants measurement input								3.09				21.54	15
Measurement Input, Maturity [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Maturity period								5 years				5 years	5 years
Measurement Input, Expected Dividend Rate [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Warrants measurement input								0				0	0
Measurement Input, Risk Free Interest Rate [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Warrants measurement input								3.58				3.91	3.84
Measurement Input, Price Volatility [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Warrants measurement input								100				97	96
Liability Instrument [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Warrant liability | $													$ 7,236
Warrant Liability [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Warrant liability | $								$ 2,887				$ 20,963
2022 Notes [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Debt converted amount | $									$ 5,600
Derivative liability eliminated | $									$ 538

Stockholders_ Equity_(Deficit_2

Stockholders’ Equity/(Deficit) / Net Parent Investment (Details Narrative) - USD ($)									1 Months Ended			12 Months Ended
	Dec. 26, 2024	Dec. 09, 2024	Sep. 26, 2024	Sep. 12, 2024	Aug. 26, 2024	Jul. 12, 2024	Jan. 31, 2024	Aug. 18, 2022	Oct. 31, 2023	Mar. 31, 2023	Aug. 31, 2022	Dec. 31, 2022	Sep. 30, 2024	Aug. 31, 2024	Dec. 31, 2023	Apr. 30, 2023	Jan. 31, 2023	Jan. 01, 2023
Class of Stock [Line Items]
Preferred stock, shares authorized													10,000,000		20,000,000
Common stock, shares authorized																10,000,000
Number of shares issued	258,836	1,000,000	258,836	1,000,000	100,000	1,600,000
Shares issued to employees												51,250
Share based compensation												$ 168,000
Preferred stock, par or stated value per share													$ 0.00001		$ 0.00001
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized													0		8,750,000
Preferred stock, shares issued													0		8,750,000
Preferred stock liquidation preference															$ 35,000,000		$ 35,000,000	$ 35,000,000
Preferred stock, par or stated value per share													$ 0.00001		$ 0.00001
Preferred stock, shares outstanding													0		8,750,000
Nonvoting Common Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized														10,000,000
Common stock, shares authorized									30,000,000			62,500,000	0		30,000,000
Number of shares issued								28,230,842			28,179,592	28,230,842
Common stock, par value									$ 0.00001				$ 0.00001		$ 0.00001
Preferred stock, par or stated value per share														$ 0.00001
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized												2,500,000	0		5,000,000	5,000,000
Preferred stock, shares issued													0		4,171,445
Stock subscription payable										$ 10,000
Proceeds from stock subscription										$ 10,000
Preferred stock, par or stated value per share													$ 0.00001		$ 0.00001
Preferred stock, shares outstanding													0		4,171,445
Series B-1 Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized													0		5,000,000	5,000,000
Preferred stock, shares issued													0		89,781
Preferred stock, par or stated value per share													$ 0.00001		$ 0.00001
Preferred stock, shares outstanding													0		89,781
Voting Common Stock [Member]
Class of Stock [Line Items]
Common stock, shares authorized									100,000,000				100,000,000		100,000,000
Common stock, par value									$ 0.00001				$ 0.00001		$ 0.00001
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized									2,500				2,500		2,500
Preferred stock, shares issued													2,500	2,500	0
Preferred stock, par or stated value per share									$ 0.00001				$ 0.00001		$ 0.00001
Preferred stock, voting rights							the Series C Preferred Stock voting rights increased from none to 13,000 votes per share		The Series C Preferred Stock had no voting rights prior to an IPO, and 13,000 votes per share upon closing of an IPO
Stock conversion description							shares will automatically convert 1:1 into common stock		The Series C Preferred Stock is not entitled to dividends, has a liquidation preference of $18.00 per share, subject to adjustment, may be converted 1:1 at any time at the option of the holder into common stock, and upon closing of an IPO, would, if transferred, automatically convert 1:1 into common stock
Preferred stock, liquidation preference per share									$ 18
Preferred stock, shares outstanding													2,500	2,500	0
Series C Preferred Stock [Member] | Chief Executive Officer [Member]
Class of Stock [Line Items]
Preferred stock, shares issued							2,500

Share Subscription Agreement (D

Share Subscription Agreement (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands										1 Months Ended		3 Months Ended			9 Months Ended
	Dec. 26, 2024	Dec. 09, 2024	Sep. 26, 2024	Sep. 12, 2024	Aug. 26, 2024	Jul. 12, 2024	Jul. 11, 2024	Jun. 27, 2024	Nov. 12, 2021	Mar. 31, 2024	Feb. 29, 2024	Sep. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Aug. 31, 2024	Jun. 30, 2024	Dec. 31, 2023	Aug. 31, 2023	Feb. 28, 2023	Sep. 30, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares issues initial public offering												$ 5,052	$ 2,819
Description of share subscription agreement															The Company may request a drawdown, or sale of common stock shares to the investors, over the five-year term of this agreement following the public listing unless terminated earlier. The amount of the drawdowns requested is limited by the trading volumes of the Company’s common stock over the 30-day period preceding the drawdown, and the price per share is equal to 90% of the average price per share over that same period. A 1% fee was due to the investors if the Company were sold in a private sale transaction rather than completing a public listing of its shares.
Sale of stock				1,000,000		1,600,000
Net proceeds				$ 325		$ 758				$ 2,819	$ 2,819				$ 7,462
Commitment fee payable										$ 2,000		1,863	2,000		1,863
Commitment fees expenses													$ 1,941		$ 1,941
Stock Issued During Period, Shares, New Issues	258,836	1,000,000	258,836	1,000,000	100,000	1,600,000
Sale of Stock, Percentage of Ownership before Transaction				90%		90%
Stock price			$ 3.25	$ 3.25	$ 1.65	$ 4.74				$ 13			$ 13				$ 1.73	$ 6.73		$ 3.28	$ 2.28	$ 3.28
Discount percentage			10%	10%	10%	10%
Fair value of contract liability			$ 2.93		$ 4.51
Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited					500,000
Number of shares			741,164	741,164	1,000,000
Liabilities Related to Investment Contracts, Fair Value Disclosure			$ 57		$ 286
Floor price			$ 3.25	$ 3.25
Stock price			$ 3.14
Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sale of stock													227,057
Net proceeds													$ 2,819
Share Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Investors sales									$ 100,000
Commitment fee percentage									2%
Shares issues initial public offering									$ 700,000
Sale of stock								3,000,000
Net proceeds								$ 1,410
Stock Issued During Period, Shares, New Issues							840,000	3,000,000
Sale of Stock, Percentage of Ownership before Transaction								90%
Stock price								$ 4.66
Discount percentage							10%	10%
Fair value of contract liability								$ 638
Fair value of contract liability							$ 4.09	$ 4.85
Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited							560,000
Number of shares							1,600,000

Schedule of Operating Lease Lia

Schedule of Operating Lease Liabilities Future minimum payments (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Less: Current lease liabilities	$ (392)	$ (362)
Total non-current lease liabilities	$ 1,055	$ 1,385

Leases, Commitments and Conti_3

Leases, Commitments and Contingencies (Details Narrative) - USD ($) $ in Thousands	1 Months Ended				9 Months Ended
	Jul. 31, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Oct. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Rent expense					$ 466	$ 504
Operating Leases [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Noncancelable lease payments					1,629
Short-term Leases [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Noncancelable lease payments					$ 74
Lease Agreement [Member] | Office Space [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Extended lease term							62 months
Operating lease liability							$ 2,293
Operating lease discount rate							7.50%
Lease Agreement [Member] | Temporary Lab and Office Space [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Extended lease term				12 months
Rent expense				$ 6
Lease Agreement Amendment [Member] | Temporary Lab and Office Space [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Rent expense			$ 7
Lease Agreement Second Amendment [Member] | Temporary Lab and Office Space [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Extended lease term	12 months
Rent expense	$ 7	$ 8

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($) $ in Thousands	1 Months Ended	9 Months Ended
	Jan. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Jan. 01, 2023
Related Party Transaction [Line Items]
Derivative liability expected future payments		$ 2,887	$ 2,573
Derivative liabilities payable to related parties			2,645
Loss on derivative			$ 72
Fibro Genesis [Member]
Related Party Transaction [Line Items]
Proceeds from equity investments in percentage	15%		15%
Derivative liability expected future payments		0	$ 0
Derivative liabilities payable to related parties		0		$ 141
Loss on derivative			$ 15
Payment paid to parent company		$ 141
Series A Preferred Stock [Member]
Related Party Transaction [Line Items]
Liquidation preference	$ 35,000			$ 35,000	$ 35,000

Schedule of Stock Based Compens

Schedule of Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 572	$ 440	$ 1,631	$ 1,333
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	82	66	248	196
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 490	$ 374	$ 1,383	$ 1,137

Schedule of Unvested Awards and

Schedule of Unvested Awards and Weighted Average Period (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)
Share-Based Payment Arrangement [Abstract]
Unrecognized stock-based compensation expense	$ 5,766
Expected weighted-average period compensation costs to be recognized	2 years 7 months 6 days

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended						9 Months Ended	12 Months Ended
	Aug. 31, 2024	Jun. 30, 2024	Mar. 31, 2024	Aug. 31, 2023	Feb. 28, 2023	Sep. 30, 2022	Sep. 30, 2024	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options, granted	25,000	6,875	216,875	2,500	3,689,750	101,250
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock options, outstanding beginning							3,788,500
Weighted-average exercise price, outstanding beginning							$ 2.31
Weighted average remaining contractual life (years), outstanding							8 years 4 months 24 days	8 years 4 months 24 days
Stock options, outstanding beginning							$ 2,989
Number of options, granted							248,750
Weighted-average exercise price, granted							$ 11.69
Weighted average remaining contractual life (years), granted							9 years 6 months
Stock options, granted							$ 34,000
Number of options, exercised
Weighted-average exercise price, exercised
Number of options, forfeited/canceled							(5,139)
Weighted-average exercise price, forfeited/canceled							$ 12.74
Weighted average remaining contractual life (years), forfeited/canceled							9 years 4 months 24 days
Stock options, outstanding ending							4,032,111	3,788,500
Weighted-average exercise price, outstanding ending							$ 2.88	$ 2.31
Stock options, outstanding, outstanding ending							$ 3,023	$ 2,989
Number of options, exercisable							1,696,210
Weighted-average exercise price, exercisable							$ 2.33
Weighted average remaining contractual term, exercisable							8 years 4 months 24 days
Stock options, outstanding, exercisable							$ 1,307

Schedule of Fair Value of Optio

Schedule of Fair Value of Option Granted Black Scholes (Details)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate, minimum	3.70%
Risk-free interest rate, maximum	4.30%
Risk-free interest rate		3.90%
Expected volatility, minimum	97%
Expected volatility, maximum	101%
Expected volatility		90%
Expected term		7 years
Expected dividend	0%	0%
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term	5 years 6 months
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term	7 years

Share-Based Compensation (Detai

Share-Based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended						3 Months Ended		9 Months Ended
	Aug. 31, 2024	Jun. 30, 2024	Mar. 31, 2024	Aug. 31, 2023	Feb. 28, 2023	Sep. 30, 2022	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 26, 2024	Sep. 12, 2024	Aug. 26, 2024	Jul. 12, 2024	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options granted	25,000	6,875	216,875	2,500	3,689,750	101,250
Strike price per share	$ 1.73	$ 6.73	$ 13	$ 3.28	$ 2.28	$ 3.28					$ 3.25	$ 3.25	$ 1.65	$ 4.74
Shares available for future issuance							8,467,889		8,467,889						8,711,500
Stock-based compensation expense							$ 572	$ 440	$ 1,631	$ 1,333
Weighted-average grant date fair value									$ 9.70
Series C Preferred Stock [Member] | Chief Executive Officer [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares issued, value									$ 45
Number of shares issued									2,500
Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expense									$ 1,631

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands								3 Months Ended
	Dec. 26, 2024	Dec. 09, 2024	Oct. 18, 2024	Sep. 26, 2024	Sep. 12, 2024	Aug. 26, 2024	Jul. 12, 2024	Sep. 30, 2024	Mar. 31, 2024
Subsequent Event [Line Items]
Number of shares issued	258,836	1,000,000		258,836	1,000,000	100,000	1,600,000
Share price				$ 2.93		$ 4.51
Number of shares issued, value								$ 5,052	$ 2,819
Subsequent Event [Member]
Subsequent Event [Line Items]
Number of shares issued			15,683
Share price			$ 2.91
Number of shares issued, value			$ 46